In this article, we will take a look at 10 High Growth European Stocks To Buy.
European equities began the last week of January in a sour mood, with investors concerned on January 26 about rising geopolitical tensions in anticipation of a Federal Reserve policy meeting and a flood of significant company earnings. While concerns over President Donald Trump’s controversial position on Greenland and the possibility of a trade dispute between the European Union and the United States have subsided, global tensions remain high.
The Stoxx 600 index surged 0.6% to 613.11 points on January 27. Meanwhile, Germany’s DAX index dropped 0.10% to 24,908.23 points, while France’s CAC 40 index rose 0.27% to 8,152.82 points. The improvements show how investors rely on company-specific factors to steer the market in an increasingly unpredictable economic climate.
Additionally, the European Union and India signed a deal on a free trade pact on the same day, the largest of its kind ever signed by either side, as they grapple with an unpredictable trade policy from the United States. While financial stocks had a particularly stellar session following the deal, automakers were widely down as the agreement reduced car tariffs from 110% to 10% for 250,000 vehicles per year. Speaking on the growth of bank stocks, Ciaran Callaghan, head of European equity research at Amundi, said the following:
“The fundamentals for banks have really improved. We expect loan growth to pick up, and we could see further positive earnings surprises from the sector this year.”
Our Methodology
Our selection criteria focused on European stocks with a 5-year revenue growth rate of (at least 20%), thus indicating solid growth. In addition, we ranked these stocks based on the number of hedge funds invested in each of them as of Q3 2025.
Why do we care about what hedge funds do? The reason is simple: our research has shown that we can outperform the market by imitating the top stock picks of the best hedge funds. Our quarterly newsletter’s strategy selects 14 small-cap and large-cap stocks every quarter and has returned 427.7% since May 2014, beating its benchmark by 264 percentage points (see more details here).
10. Genmab A/S (NASDAQ:GMAB)
5-Year Revenue Growth Rate: 31.15%
Number of Hedge Fund Holders: 20
Genmab A/S (NASDAQ:GMAB) ranks among the best high growth European stocks to buy. On January 20, H.C. Wainwright cut its price target for Genmab A/S (NASDAQ:GMAB) to $39 from $41, retaining a Buy rating on the company’s shares. The change comes after Genmab and partner AbbVie announced that their Phase 3 EPCORE DLBCL-1 trial found no meaningful improvement in the overall survival for EPKINLY (epcoritamab) monotherapy when compared to standard treatments in second-line diffuse large B-cell lymphoma (DLBCL) patients.
Regardless of this shortcoming, H.C. Wainwright believes EPKINLY will likely maintain its 2023 accelerated clearance for third-line DLBCL treatment, at least until the results of two additional ongoing Phase 3 trials are released. In this context, the firm referenced a precedent set by Roche’s Columvi, which retained its accelerated approval despite missing overall survival targets in a similar patient group while expecting more study findings.
Genmab A/S (NASDAQ:GMAB) is a biotechnology company specializing in oncology, developing innovative antibody-based therapies for cancer treatment. Its late-stage pipeline includes promising programs like Rina‑S and EPKINLY.
9. BeOne Medicines Ltd. (NASDAQ:ONC)
5-Year Revenue Growth Rate: 54.79%
Number of Hedge Fund Holders: 21
BeOne Medicines Ltd. (NASDAQ:ONC) ranks among the best high growth European stocks to buy. On January 7, Citizens reaffirmed its Market Outperform rating and $396 price target for BeOne Medicines Ltd. (NASDAQ:ONC), citing strong effectiveness results from a Phase 3 trial in gastric cancer patients. BeOne Medicines Ltd. (NASDAQ:ONC) and Jazz Pharmaceutics shared further findings from the HERIZON-GEA-01 trial, which revealed high efficacy in patients with advanced gastric or gastroesophageal adenocarcinoma (GEA).
Citizens observed that BeOne’s Brukinsa was on track to generate about $3.8 billion in revenue in 2025, thanks to an impressive development pipeline that includes numerous assets across diverse indications.
The company also revealed the first clearance for sonrotoclax, its next-generation BCL2 inhibitor, which Citizens anticipates could contribute to subsequent approvals worldwide.
At the same time, the firm emphasized BeOne’s $4.1 billion cash position and stated that the recent share price decline represented a “unique buying opportunity” in one of the world’s leading hematology/oncology companies.
BeOne Medicines Ltd. (NASDAQ:ONC) is a global biotechnology company that specializes in oncology medicines, particularly for blood cancers and solid tumors.
8. BioNTech SE (NASDAQ:BNTX)
5-Year Revenue Growth Rate: 89.57%
Number of Hedge Fund Holders: 24
BioNTech SE (NASDAQ:BNTX) ranks among the best high growth European stocks to buy. On January 16, Goldman Sachs upgraded BioNTech SE (NASDAQ:BNTX) from Neutral to Buy and boosted its price target from $115 to $142, highlighting the company’s key position in oncology. According to the firm, BioNTech SE (NASDAQ:BNTX) stands “at the nexus of significant developments occurring in the oncology field,” particularly in next-generation immuno-oncology and antibody-drug conjugates (ADCs).
Goldman Sachs noted BioNTech’s extensive portfolio of programs aimed at an estimated market worth more than $100 billion, with key results coming in 2026 that could position the company as a pioneer in the next stage of oncology treatments.
However, Goldman Sachs recognized potential rivalry in BioNTech’s clinical development domains, including competition from other bispecific antibody companies and late-stage ADC initiatives. However, it determined that BioNTech has a “unique risk/reward opportunity” in the rapidly changing oncology field.
BioNTech SE (NASDAQ:BNTX) is a German biotechnology company that develops and commercializes novel immunotherapies and vaccines for cancer and infectious diseases.
7. Sportradar Group AG (NASDAQ:SRAD)
5-Year Revenue Growth Rate: 22.96%
Number of Hedge Fund Holders: 31
Sportradar Group AG (NASDAQ:SRAD) ranks among the best high growth European stocks to buy. Stifel began coverage of Sportradar Group AG (NASDAQ:SRAD) with a Buy rating and a $28 price target on January 21. Stifel believes Sportradar’s dominant scale and portfolio variety position it well against rivals for new rights, even though the company remains in the early phases of upselling consumers to higher profit and value products.
The firm emphasizes that the online sports betting industry seems to be forming into a rational duopoly, reducing displacement risk, while near-term rights inflation and margin growth are de-risked owing to ideal timing in the rights contract period.
Stifel notes that, while Sportradar Group AG (NASDAQ:SRAD) shares have almost doubled in the span of two years, the stock has pulled back in the last five months, providing what the firm considers an attractive entry point.
Sportradar Group AG (NASDAQ:SRAD) is a global sports technology company providing data and software solutions to sports federations, media, and sports betting operators.
6. Globant S.A. (NYSE:GLOB)
5-Year Revenue Growth Rate: 29.65%
Number of Hedge Fund Holders: 32
Globant S.A. (NYSE:GLOB) ranks among the best high growth European stocks to buy. On January 20, UBS boosted its price target for Globant S.A. (NYSE:GLOB) to $75 from $70 while keeping a Neutral rating on the company’s shares. Globant is expected to report a 6% year-over-year decrease in revenue to $607 million in the fourth quarter of 2025, somewhat higher than the company’s projection of $605 million.
UBS predicts that Globant’s adjusted gross margin would fall to 37.8% owing to foreign exchange challenges, though adjusted EBIT margin is projected to climb to 15.3%, beating the company’s guidance of “at least” 15%.
UBS forecasts 1.6% year-over-year growth in 2026, indicating that the IT services market has stabilized but has not improved significantly since 2025. The firm sees potential for expansion from new clients, including Riot Games and YPF, but prefers to wait for implementation before making a more positive assessment.
Globant S.A. (NYSE:GLOB) is a technology company that provides digital and cognitive transformation services for businesses, creating “digitally-native” products and helping organizations evolve their technology and business strategies.
5. Genius Sports Limited (NYSE:GENI)
5-Year Revenue Growth Rate: 34.84%
Number of Hedge Fund Holders: 40
Genius Sports Limited (NYSE:GENI) ranks among the best high growth European stocks to buy. On January 21, Stifel began coverage of Genius Sports Limited (NYSE:GENI) with a Hold rating and a $10 price target, citing the company’s “attractive ‘picks & shovels’ model” in the online sports betting industry, as well as its recurring revenues, solid net revenue retention, wide moat, and financial potential.
Although investors have long been concerned about competition for data rights, Stifel said that the industry seems to be solidifying into a “rational duopoly,” with Genius Sports’ contra-service model adding to the switching costs for consumers.
Driven by anticipated development in its AdTech division, the company’s management has set financial targets for 2028 that involve compound annual growth rates of 22% for revenue and 39% for EBITDA over three years. Given the stock’s premium multiple and possible challenges to the company’s long-term goals, Stifel believes the risk-reward ratio is “balanced” despite the “attractive” multi-year underlying outlook.
Genius Sports Limited (NYSE:GENI) is a global sports data and technology company powering the sports, betting, and media ecosystem. It captures and distributes live sports data, streaming, analytics, and integrity services to leagues, sportsbooks, and broadcasters worldwide.
4. Ascendis Pharma A/S (NASDAQ:ASND)
5-Year Revenue Growth Rate: 92.27%
Number of Hedge Fund Holders: 49
Ascendis Pharma A/S (NASDAQ:ASND) ranks among the best high growth European stocks to buy. On January 20, RBC Capital increased Ascendis Pharma A/S (NASDAQ:ASND)’s price target to $250 from $245 while maintaining an Outperform rating on the company. The firm’s improved projection comes after Ascendis Pharma A/S (NASDAQ:ASND) announced major goals for 2026, with the company estimating maintaining launch momentum for Yorvipath with no drop in patient intakes.
Ascendis Pharma A/S (NASDAQ:ASND) stated that the European potential could be more significant, with 150,000-200,000 patients vs 70,000-90,000 in the US, though the complex payer system demands patience. The company anticipates that the revenue split would eventually come to 60:40 U.S. to non-U.S.
In terms of financial estimates, Ascendis Pharma A/S (NASDAQ:ASND) reiterated its objective of €500 million in operating cash flow for this year and more than €5 billion in top-line revenue by 2030, in contrast to the consensus of around €3.5 billion, with Yorvipath predicted to earn €5-8 billion at its height.
Ascendis Pharma A/S (NASDAQ:ASND) is a biopharmaceutical company that develops and distributes novel treatments for unmet medical needs, especially in the fields of oncology and endocrinology.
3. Argenx SE (NASDAQ:ARGX)
5-Year Revenue Growth Rate: 94.72%
Number of Hedge Fund Holders: 50
Argenx SE (NASDAQ:ARGX) ranks among the best high growth European stocks to buy. On January 12, William Blair maintained its Outperform rating on Argenx SE (NASDAQ:ARGX), citing robust sales growth in the company’s Vyvgart brand. The firm reports that Vyvgart sales stay ahead of expectations and demonstrate solid momentum, which it expects to last through 2026 across authorized applications in MG (myasthenia gravis) and CIDP.
The firm also emphasized the potential of Argenx’s other clinical products, including empasiprubart in MMN (multifocal motor neuropathy), which the firm sees as having massive potential, with pivotal EMPASSION data coming in the fourth quarter of 2026.
Moreover, the FDA recently agreed to give priority review to a supplemental biologics licensing application for Vyvgart. The application aims to increase Vyvgart’s usage in treating adults with acetylcholine receptor antibody-seronegative generalized myasthenia gravis (gMG), increasing the patient group eligible for the drug.
Argenx SE (NASDAQ:ARGX) is a biotech company that develops treatments for severe autoimmune diseases. The company operates through four segments: the United States, Japan, EMEA, and China.
2. On Holding AG (NYSE:ONON)
5-Year Revenue Growth Rate: 57.83%
Number of Hedge Fund Holders: 52
On Holding AG (NYSE:ONON) ranks among the best high growth European stocks to buy. KeyBanc reduced its price target for On Holding AG (NYSE:ONON) to $58 from $68 on January 22, while maintaining an Overweight rating on the company’s shares. The cut came in spite of KeyBanc naming On Holding AG (NYSE:ONON) as one of the “best growth stories” for 2026.
KeyBanc continues to be optimistic about On Holding’s core strengths, citing its “strong growth setup” fueled by global momentum, product pipeline strength, pricing flexibility, and continued customer loyalty.
Meanwhile, on January 19, Goldman Sachs upgraded On Holding AG (NYSE:ONON) from Neutral to Buy and increased its price target to $59 from $52. The upgrade came as Goldman Sachs determined that the stock’s de-rating over the last year provides a compelling entry point for buyers.
Goldman Sachs expects On Holding AG (NYSE:ONON) to outperform fourth-quarter 2025 market projections, citing high-frequency data indicating a solid holiday season for the brand.
On Holding AG (NYSE:ONON) is involved in the development and distribution of sports products, including apparel, footwear, and accessories. The company sells its products across the globe through global distributors, independent retailers, an online presence, and its stores.
1. Amer Sports Inc. (NYSE:AS)
5-Year Revenue Growth Rate: 20.65%
Number of Hedge Fund Holders: 63
Amer Sports Inc. (NYSE:AS) ranks among the best high growth European stocks to buy. On January 14, Truist Securities raised its price target for Amer Sports Inc. (NYSE:AS) to $46 from $45, while keeping a Buy rating on the company’s shares. The firm noted “durable growth levers across the business” as its main justification for maintaining a bullish perspective on the company.
According to Truist, Amer Sports Inc. (NYSE:AS) management has defined a long-term strategy for 2030, which involves a revenue compound annual growth rate (CAGR) within the low double-digit to mid-teens range and an annual adjusted operating margin boost of 30-70 basis points or higher.
These ambitions correspond to a 5-year earnings per share CAGR of more than 25% and earnings per share of over $2.50 in fiscal year 2030, both of which Truist says are realistic given the company’s efforts to grow across a number of brands, as well as its proven execution track record in China.
Amer Sports Inc. (NYSE:AS) designs, manufactures, markets, distributes, and sells sports equipment, apparel, footwear, and accessories. It operates through three segments: Technical Apparel, Outdoor Performance, and Ball & Racquet Sports.
While we acknowledge the potential of AS to grow, our conviction lies in the belief that some AI stocks hold greater promise for delivering higher returns and have limited downside risk. If you are looking for an AI stock that is more promising than AS and that has 100x upside potential, check out our report about this cheapest AI stock.
READ NEXT: 10 Best Magic Formula Stocks for 2025 and 10 Best Retirement Stocks to Buy According to Hedge Funds.
Disclosure: None. Insider Monkey focuses on uncovering the best investment ideas of hedge funds and insiders. Please subscribe to our free daily e-newsletter to get the latest investment ideas from hedge funds’ investor letters by entering your email address below.
